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ABSTRACT 1 
Death Receptor 3 (DR3, TNFRSF25) and its TNF-like ligand TL1A (TNFSF15) control a number of 2 
processes in inflammatory diseases through the expansion of effector T cells and the induction of 3 
pro-inflammatory cytokines from myeloid and innate lymphoid cells. Here, using wildtype (DR3
+/+
) 4 
and DR3 knockout (DR3
-/-
) mice, we show that the DR3/TL1A pathway triggers the release of 5 
multiple chemokines following acute peritoneal inflammation initiated by a single application of 6 
Staphylococcus epidermidis supernatant (SES), correlating with the infiltration of multiple leukocyte 7 
subsets. In contrast, leukocyte infiltration was not DR3-dependent following viral challenge with 8 
murine cytomegalovirus (MCMV). DR3 expression was recorded on connective tissue stroma, which 9 
provided DR3-dependent release of CCL2 (MCP-1), CCL7 (MCP-3), CXCL1 (KC), and CXCL13 10 
(BCA-1). CCL3 (MIP-1!), CCL4 (MIP-1") and CXCL10 (IP10) production was also DR3-11 
dependent, but qRT-PCR showed that their derivation was not stromal. In vitro cultures identified 12 
resident macrophages as a DR3-dependent source of CCL3. Whether DR3 signaling could contribute 13 
to a related peritoneal pathology was then tested using multiple applications of SES, the repetitive 14 
inflammatory episodes of which lead to peritoneal membrane thickening and collagen deposition. 15 
Unlike their DR3
+/+
 counterparts, DR3
-/-
 mice did not develop fibrosis of the mesothelial layer. Thus, 16 
this work describes both a novel function and essential requirement for the DR3/TL1A pathway in 17 
acute, resolving and chronic inflammation in the peritoneal cavity.  18 
19 
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INTRODUCTION 1 
Death Receptor 3 (DR3, TRAMP, LARD, WSL-1, Apo-3, TR3, TNFRSF25)
1-6
, a member of the 2 
tumor necrosis factor receptor superfamily (TNFRSF), and its TNFSF ligand TL1A (TNFSF15) 
7
, 3 
have emerged as major regulators of inflammation and immunity. Genome-wide association studies 4 
(GWAS) have consistently linked polymorphisms around the TNFSF15 gene as a risk factor in 5 
inflammatory bowel diseases (IBD) such as ulcerative colitis, Crohn’s disease and/or irritable bowel 6 
syndrome 
8-11
, and in the arthritic disease ankylosing spondylitis 
12
, with associations also reported 7 
with primary billiary cirrhosis 
13
. Furthermore, variation in the TNFRSF25 gene locus has been 8 
suggested as a risk factor in rheumatoid arthritis (RA) 
14
, while other genetic studies have associated 9 
the TNFSF15 gene with leprosy 
15
, implicating a further role for the DR3/TL1A axis in pathogenic 10 
immunity. 11 
 12 
These wide-ranging links to multiple pathologies have been supported by in vitro and in vivo studies 13 
in both man and mouse. Levels of serum and tissue TL1A are increased in RA 
16
, IBD 
17
, psoriasis 
18
, 14 
primary billiary cirrhosis 
19
 and ankylosing spondylitis 
20
, while mice overexpressing TL1A develop 15 
colitis or ileitis 
21-23
. In contrast, mice deficient for DR3 or TL1A, or those expressing dominant 16 
negative forms of DR3 are resistant to multiple models of inflammatory and autoimmune disease 
24-
17 
31
, or exhibit impaired immunity to bacterial or viral pathogens 
32, 33
 with a more debated impact on 18 
immunity to parasitic worms 
34, 35
. Much of DR3 function has been attributed to its expression on T 19 
cells (CD4
+
 regardless of lineage or CD8
+
) and the capacity of TL1A, either directly or indirectly, to 20 
drive the proliferation of pathogenic effector T cell numbers 
26, 27, 36, 37
. A single study also suggests a 21 
role in inhibiting proliferation of B cells 
38
. This has defined significant roles for the DR3/TL1A 22 
pathway in adaptive immune responses.  23 
 24 
However, DR3 expression is also found on innate immune cell and non-hematopoietic lineages. DR3 25 
signaling on myeloid cells influences myeloid differentiation 
30, 39
, while on NKT and innate 26 
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lymphoid cells (ILCs), triggers effector cytokine release and expansion essential for the development 1 
of airway inflammation 
25, 34
. Further, DR3
-/-
 mice exhibit behavioural defects associated with 2 
impaired corticostriatal innervation controlled by DR3 expression on neurones 
40
 and its expression 3 
on tubular epithelial cells regulates renal inflammation and injury caused by reperfusion 
41, 42
. On 4 
osteoblasts, DR3 can trigger apoptosis in vitro 
43
 or control bone mineral apposition in vivo 
44
. These 5 
findings indicate that the DR3/TL1A pathway has intrinsic functions and also controls early events in 6 
immune processes in addition to the more established roles in acquired immunity. 7 
 8 
In this report, we further investigated the in vivo role of the DR3/TL1A pathway using sterile 9 
challenge of Staphylococcus epidermidis supernatant (SES) in the peritoneal cavity 
45, 46
. As a single 10 
application, this system mimics a resolving inflammatory response that returns to baseline levels 
45
, 11 
allowing scrutiny of infiltrating cells and soluble factors in peritoneal washouts within hours of the 12 
challenge. Using multiple applications, pathology develops in the form of peritoneal membrane 13 
fibrosis 
47
, mirroring the pathology associated with repeated bacterial infections in renal patients on 14 
peritoneal dialysis. Consequently, we show that the DR3/TL1A axis shapes the inflammatory 15 
response within the peritoneum and report a previously unappreciated role for DR3 in controlling 16 
inflammation via modulation of chemokine expression by both hematopoietic and stromal cells. 17 
18 
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MATERIALS AND METHODS 1 
Animals 2 
Age-matched DR3
-/-
 and DR3
+/+
 littermates of 8-12 weeks of age on a C57BL/6 background were 3 
used in experiments, derived from a DR3
het
 colony that was founded from mice provided by CRUK 4 
48
. For peritoneal challenge with SES, animals of mixed sex were used as no significant differences in 5 
peritoneal leukocyte content of male and female mice were observed, either at baseline or during the 6 
course of experiments (data not shown). Irrespective, the male:female ratio in each DR3
+/+
 and DR3
-/-
 7 
group for each timepoint were matched. For challenge with MCMV, all animals used were male. All 8 
procedures were approved by the Local Research Ethics Committee and performed in accordance 9 
with Home Office approved license PPLs 30/2401 (for SES), 30/2442 and 30/2580 (for MCMV).  10 
 11 
Immunohistochemistry  12 
Briefly, peritoneal membranes were harvested and fixed in neutral buffered formal saline and 13 
permeated with paraffin wax before 5!m sectioning. Sections were rehydrated and endogenous 14 
peroxidase activity was blocked. Antigen unmasking was achieved by incubating the sections in 15 
Proteinase K (20 !g/ml in TE buffer; Sigma) for 10 mins. Following blocking steps (20% goat serum 16 
and streptavidin/biotin blocking kit (Vector Laboratories), sections were incubated overnight with 4 17 
!g/ml goat biotinylated anti-DR3 (R&D systems) or isotype controls diluted in PBS followed by 18 
streptavidin-HRPO secondary antibody (Vector Laboratories) as per manufacturer’s instructions. 19 
Positive staining was visualized using a DAB chromogen (Vector Laboratories). Collagen was 20 
visualized using van Gieson stain. Sections were counterstained with hematoxylin, dehydrated and 21 
mounted in DPX.  Images were captured using an Olympus N457 or Canon 100D digital camera and 22 
positive staining analyzed using Adobe Photoshop CS3.5. Randomly selected areas were used for 23 
analysis with the average from 5 being used to generate values for each section. 24 
 25 
qRT-PCR 26 
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Total RNA was extracted following manufacturer’s instructions using a RNAeasy mini kit (Qiagen, 1 
Crawley, UK) from snap frozen and powdered peritoneal membranes or pelleted macrophages. 2 
cDNA synthesis and PCR was performed using systems and primers generated through Primer 3 
Design (Southampton, UK) on an iCycler qPCR machine (Biorad, Hemel Hempstead, UK) with "-4 
actin as the housekeeping control gene. Relative Quantity (RQ) was calculated after subtracting the 5 
negative control. Primers used (forward first, reverse second) were as follows:  6 
CCL2 (5’-CCCAATGAGTAGGCTGGAGA-3’ and 5’-TCTGGACCCATTCCTTCTTG-3’);  7 
CCL3 (5’-TTTTGAAACCAGCAGCCTTT-3’ and 5’-CTGCCTCCAAGACTCTCAGG-3’);  8 
CCL4 (5’-CCCACTTCCTGCTGTTTCTC-3’ and 5’-CTCACTGGGGTTAGCACAGA-3’);  9 
CCL5 (5’-GTGCCCACGTCAAGGAGTAT-3’ and 5’-CCACTTCTTCTCTGGGTTGG-3’);  10 
CCL7 (5’-CCCAAGAGGAATCTCAAGAGC-3’ and 5’-ATAGCCTCCTCGACCCACTT-3’);  11 
CXCL1 (5’-GCACCCAAACCGAAGTCATA-3’ and 5’-AGGTGCCATCAGAGCAGTCT-3’);  12 
CXCL2 (5’-AAAGTTTGCCTTGACCCTGA-3’ and 5’-CTTTGGTTCTTCCGTTGAGG-3’);  13 
CXCL5 (5’-GCCCTACGGTGGAAGTCATA-3’ and 5’-GTGCATTCCGCTTAGCTTTC-3’);  14 
CXCL10 (5’-TGAATCCGGAATCTAAGACCA-3’ and 5’-GAGGCTCTCTGCTGTCCATC-3’);  15 
CXCL13 (5’-TCGTGCCAAATGGTTACAAA-3’ and 5’-GGTGCAGGTGTGTCTTTTGA-3’);  16 
TL1A (5’-CAGCAGAAGGATGGCAGA-3’ and 5’-CTCTGGCCTGTGTCTACA-3’). 17 
 18 
Preparation of SES, determination of biological activity and the SES model of peritoneal 19 
challenge 20 
SES was prepared and used in peritoneal challenge as described previously 
46, 47
. Supernatants were 21 
filtered to remove live bacteria, lyophilized and stored at -70˚C. Biological activity was determined 22 
by its capacity to induce IL6 release from RAW 264 cells in a 24 hr culture, measured by ELISA 23 
(BD Pharmingen OpEIA; BD Biosciences, Oxford, UK). 24 
 25 
Challenge with MCMV 26 
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Mice were challenged itraperitoneally (i.p.) with 5 x 10
4
 plaque-forming units of MCMV Smith 1 
strain (American Type Culture Collection, Manassa, VA, USA), as previously described 
49
. 2 
 3 
Flow cytometry 4 
Following peritoneal lavage and centrifugation to isolate leukocytes, samples were treated with Fc 5 
block (BD Pharmingen) and then stained at 4˚C for 25 mins with combinations of the following pre-6 
conjugated mAbs: CD19-FITC, CD8a-FITC, NK1.1-PE, Gr-1-PerCP-Cy5.5, CD4-PerCP-Cy5.5, 7 
CD11c-PE-Cy7, Ly6G-V450, CD44-V450, CD11b-APC-Cy7, CD3-APC-Cy7 (all BD Biosciences); 8 
B220-PE, F4/80-APC (Invitrogen); Ly6B.2-PE (AbD Serotec); TCR!"-APC (Caltag). Samples were 9 
then washed, fixed in 1% paraformaldehyde before running and analysis on a CyAnTM ADP Flow 10 
Cytometer using Summit software (Beckman Coulter). Cell subsets were identified using the 11 
following criteria: neutrophils (7/4
+
, Ly6G
+
), resident macrophages (F4/80
+
CD11b
+
), inflammatory 12 
macrophages (F4/80
int
CD11b
int
), eosinophils (F4/80
int
CD11b
int
SSC
hi
), NK cells (NK1.1
+!"TCR-), 13 
NKT cells (NK1.1
+!"TCR+), T cells (CD3+!"TCR+) and B cells (CD19+B220+). 14 
 15 
ELISAs and chemokine arrays 16 
ELISAs were performed following manufacturers’ instructions. For murine CCL2, CCL3, CCL5, 17 
CCL5, CXCL1. CXCL2, CXCL5, CXCL10 and CXCL13, ELISAs were obtained from R&D 18 
Systems (Abingdon, UK). ELISA for murine CCL7 was obtained from Antigenix America (NY 19 
11746, USA). For determining concentration of chemokines in cultures of resident macrophages, the 20 
Legendplex
TM
 mouse proinflammatory chemokine panel was used following manufacturer’s 21 
instructions (Biolegend). 22 
 23 
Statistical analysis 24 
Staining readouts were percentages, therefore, non-parametric Mann-Whitney U tests were used for 25 
statistical analysis. For protein concentrations from ELISAs and RQ from qRT-PCR, student’s t-26 
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Tests and ANOVAs were used. Analyses were performed on GraphPad Prizm - p values of <0.05 1 
were considered significant and values of <0.01 were considered highly significant. 2 
3 
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RESULTS 1 
DR3 and TL1A expression in the peritoneal cavity following SES challenge 2 
The DR3/TL1A pathway has been shown to be essential in the development of a number of models 3 
of disease involving intraperitoneal priming or challenge 
25-27, 30, 32, 33
, but little has been reported 4 
about DR3 and TL1A expression patterns in the peritoneal tissue and cavity during this process. DR3 5 
expression in the mesothelial layer of the peritoneal membrane was first investigated, before and after 6 
SES challenge by staining of sections using a polyclonal antibody. Anti-DR3 showed minimal 7 
staining on DR3
-/-
 peritoneal mesothelial layers (0.25 ± 0.08% positive pixels), but a significant 8 
signal was recorded from DR3
+/+
 samples, in the absence of (6.5 ± 0.3%) and up to 12 hrs post-9 
challenge (7.6 ± 1.6%) before becoming negative after 24 hrs (0.08 ± 0.04%) (Fig. 1A, B). DR3 was 10 
also found on CD4
+
, CD8
+
 and NKT cells within the peritoneal cavity, in agreement with previous 11 
reports studying DR3 expression in splenocytes (
25, 33
 and data not shown). This data shows for the 12 
first time that DR3 is present on the stroma of the peritoneal cavity. In addition, expression of TL1A 13 
mRNA was measured using qRT-PCR on peritoneal membrane sections, as well as from resident 14 
peritoneal macrophages isolated by cell sorting (F4/80
+
CD11b
+
) and treated in vitro with SES. Whilst 15 
the mesothelial layers were negative for TL1A throughout the timecourse (Fig. 1C), TL1A mRNA 16 
was triggered from resident peritoneal macrophages within 1 hr of SES treatment, irrespective of 17 
their derivation from DR3
+/+
 or DR3
-/-
 mice (Fig. 1D). Thus, bacterial challenge in the peritoneal 18 
cavity primarily induces TL1A from resident macrophages, not stroma, but responses to TL1A can 19 
come from DR3 on both stroma and leukocytes.  20 
 21 
Leukocyte accumulation is impaired in the absence of DR3 22 
Leukocyte infiltration of the peritoneal cavity following SES challenge was next examined in the 23 
presence or absence of DR3. The composition of inflammatory cells in the peritoneal lavage was 24 
assessed using multiparameter flow cytometry and 2 panels of mAbs defining myeloid lineages and 25 
lymphoid populations (see Materials and Methods). Before challenge, there were no differences in 26 
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the leukocyte content of DR3
-/-
 and DR3
+/+
 peripheral blood or peritoneal lavage (Supplemental 1 
Table 1), showing that the absence of DR3 did not influence the baseline cellular constitution of the 2 
circulation or peritoneal cavity. The progression of this model from inflammatory insult to its 3 
resolution has been well-characterized, demonstrating a biphasic cellular infiltration predominantly 4 
consisting of neutrophils that peaks in the first 6 hrs and declines thereafter. Increasing numbers of 5 
other cell types follows, peaking after 48 hrs, before falling away over 96 hrs (
45, 46
 and Fig. 2). In 6 
DR3
-/-
 mice, significantly lower numbers of neutrophils in the early stage were observed following 7 
SES challenge compared to their DR3
+/+
 counterparts. Interestingly, viral challenge with murine 8 
cytomegalovirus (MCMV) induced considerably less neutrophil accumulation and showed no 9 
differences between DR3
+/+
 and DR3
-/-
 mice (Fig 2A) , consistent with reports that neutrophil 10 
recruitment following MCMV challenge is IL-22 dependent 
50
. During the second phase after SES 11 
challenge, eosinophils, inflammatory macrophages, T cells, B cells and NKT cells were decreased in 12 
number (Fig 2B). While the profile of resident macrophages and NK cell numbers were not 13 
significantly different between DR3
+/+
 and DR3
-/-
 mice throughout the time course, peritoneal B cell 14 
numbers remained significantly higher in DR3
+/+
 animals by 96 hrs post-challenge (Fig. 2B). Overall, 15 
there was an intrinsic defect in the accumulation of leukocytes in DR3
-/-
 mice after SES challenge in 16 
the peritoneal cavity. 17 
 18 
Proliferation is unaltered in leukocytes from DR3
-/-
 mice 19 
Reduced numbers of effector cells, normally at the site of pathology, have been reported in the 20 
absence of DR3 in a variety of different pathological settings, primarily being ascribed to defects in 21 
proliferation 
25-27, 32-34
. We, therefore, measured the levels of proliferation of cells from peritoneal 22 
lavage using detection of Ki67 at 48 hrs post-SES challenge, when there were peak numbers of 23 
infiltrating leukocytes. Surprisingly, there were no differences in Ki67 staining of any of the cell 24 
subsets when comparing DR3
+/+
 and DR3
-/-
 mice (Supplemental Fig. 1 and Supplemental Table 2), 25 
indicating that at this early stage of the inflammatory process, DR3 was regulating a distinct 26 
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mechanism of cellular accumulation. Because DR3 contains a death-inducing intracellular domain, 1 
apoptosis using Annexin-V staining was also measured, but consistent with other reports 
33, 51
, the 2 
absence of DR3 did not alter the levels of cell death in peritoneal leukocytes (data not shown). The 3 
DR3/TL1A pathway therefore regulated peritoneal leukocyte numbers early after bacterial challenge 4 
with a mechanism that was independent of proliferation and cell death.  5 
 6 
Levels of multiple chemokines are impaired in DR3
-/-
 mice following SES challenge 7 
Another possible explanation for the defect in accumulation of cellular infiltrate is that DR3 regulates 8 
leukocyte recruitment. To ensure that the absence of DR3 did not adversely influence baseline levels, 9 
cell-free supernatant from peritoneal lavages of unchallenged DR3
+/+
 and DR3
-/-
 mice were tested for 10 
a range of chemokines capable of attracting virtually every subset of leukocytes between them. No 11 
significant differences were found at baseline, with detectable levels of CCL3, CCL4, CXCL5 12 
(targeting neutrophils, monocytes), CXCL10 (T cells, NK cells) and CXCL13 (B cells), while CCL2, 13 
CCL5, CCL7 (dendritic cells, monocytes, T cells), CXCL1 and CXCL2 (neutrophils) were below 14 
levels of detection of their specific kits (Supplemental Fig. 2). The kinetics of chemokine release 15 
were then investigated in the peritoneal lavage of DR3
+/+
 and DR3
-/-
 mice challenged with SES. 16 
While some chemokines including CCL5, CXCL2 and CXCL5 showed no differences between 17 
genotypes, the expression of CCL2, CCL3, CCL4, CCL7, CXCL1, CXCL10, CXCL13 were all 18 
significantly impaired in DR3
-/-
, as compared to DR3
+/+
 mice, although not necessarily at the same 19 
timepoint as when peak concentrations were observed (Fig. 3A). In DR3
-/-
 mice, CCL2, CCL7 and 20 
CXCL1 were significantly reduced at 1 hr; CXCL10 at 3 hrs; CCL3 and CCL4 at 6 hrs; and CXCL13 21 
at 24 hrs.  22 
 23 
Select chemokines are differentially produced from the stroma or resident macrophages in a 24 
DR3-dependent fashion  25 
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Chemokines can be derived from both stromal and hematopoietic cells. To delineate between these 1 
potential sources, qRT-PCR for the messages of all of the above chemokines were performed on 2 
RNA extracted from DR3
+/+
 and DR3
-/-
 mesothelial layers at timepoints between 1 and 24 hrs 3 
following SES challenge. Those showing no significant differences in protein levels between DR3
-/-
 4 
and DR3
+/+
 mice (CCL5, CXCL2 and CXCL5) also showed no significant differences in message. In 5 
contrast, of the remaining 7, only CCL2, CCL7, CXCL1 and CXCL13 (attractants of dendritic cells, 6 
neutrophils, eosinophils, memory T and B cells) demonstrated a significant reduction in message 7 
from DR3
-/-
 compared to DR3
+/+
 mesothelial layers (Fig. 3B), implicating the stroma as a significant 8 
DR3-dependent source of these chemokines and suggesting non-stromal cells are the DR3-dependent 9 
source of the others. To further investigate this, resident macrophages (the largest innate immune 10 
leukocyte population in the unchallenged peritoneal cavity – see Supplemental Table 1) were 11 
extracted from DR3
+/+
 and DR3
-/-
 mice, pooled and challenged with SES in vitro. Of 13 chemokines 12 
studied, only CCL3 and CCL4 were recorded at levels above the detection limit of the array. DR3
+/+
 13 
resident macrophages produced significantly more CCL3, but not CCL4, compared to DR3
-/-
 resident 14 
macrophages in response to SES (Fig. 3C). The overall conclusion is that DR3 signaling controls 15 
recruitment of multiple leukocyte subsets following bacterial challenge in the peritoneal cavity by a 16 
broad release of chemokines, some of which come from stroma, while others are derived from non-17 
stromal cell types including resident macrophages within the peritoneal cavity. 18 
 19 
DR3 deficiency protects against pathology of SES-induced chronic inflammation  20 
To test whether DR3 signaling could contribute to pathology in a related model of disease, DR3
-/-
 21 
animals were challenged with multiple serial applications of SES, a system designed to mimic the 22 
fibrosis of the peritoneal membrane observed in peritoneal dialysis patients following persistent and 23 
regular bacterial infections in the peritoneal cavity 
47
. Thickening of the mesothelial layer and 24 
increased deposition of collagen was observed in DR3
+/+
 mice, but DR3
-/-
 mice showed resistance to 25 
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this (Fig. 4), demonstrating an essential requirement for DR3 in the development of this fibrotic 1 
pathology.  2 
3 
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DISCUSSION 1 
In recent years, the DR3/TL1A pathway has emerged as a master regulator of inflammatory and 2 
autoimmune disease, as well as a co-ordinator of immune responses to a variety of pathogens. This is 3 
in the context of DR3
-/-
 mice showing no impairments in the development of their immune systems, 4 
constitution of their immune (or other) organs 
48
 or intrinsic extrathymic T cell trafficking 
26
.  Much 5 
of the in vivo research in the field has used models of disease involving antigen priming or pathogen 6 
challenge in the peritoneal cavity, and have demonstrated that antigen-specific splenic responses 7 
following such challenges are relatively normal in the absence of DR3 indicating that immune 8 
priming is intact. Here, we show that the DR3/TL1A pathway controls the very earliest of immune 9 
processes during peritoneal challenge, regulating the production of chemokines that draws pro-10 
inflammatory leukocytes into sites of inflammation. This effect is dependent on the type of challenge, 11 
with SES, but not MCMV, inducing DR3-dependent leukocyte infiltration. There is the possibility 12 
that the DR3/TL1A pathway interacts with specific TLR signaling pathways as Staphyloccus 13 
epidermidis is recognized through TLR2 
52
, while MCMV triggers TLR3 and 9 
53
 and induces 14 
neutrophil recruitment through IL-22 
50
.  15 
 16 
Prior to this report, DR3 function has primarily been attributed to the expression of DR3 on multiple 17 
cell types of the hematopoietic lineage, ranging from NKT, CD4
+
, CD8
+
 T and B cells to ILCs, 18 
macrophages and neutrophils. This is the first report of significant DR3 expression on a stromal layer 19 
in an in vivo setting and in the absence of active immune responses. Previous studies have indicated 20 
that DR3 is inducible on stroma by pro-inflammatory events, as has been described for tubular 21 
epithelial cells following ischemic injury 
41
 and possibly in joints undergoing antigen-induced 22 
arthritis, although the latter could be attributed to infiltrating cells 
51
. More intriguingly, stromal DR3 23 
expression seems to be closely regulated in the peritoneal cavity, with the signal disappearing 24 hrs 24 
after SES challenge. In contrast, although endothelial cells have been reported to release TL1A 
7
, its 25 
major source following SES challenge was resident macrophages, occurring within an hour of 26 
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stimulation and independent of DR3 expression (Fig. 1). This is in agreement with previous reports 1 
showing cells of the myeloid lineage respond to bacterial challenges by rapid TL1A release 
26, 32
. 2 
 3 
DR3-dependent release of some chemokines has been previously reported, but not on the scale shown 4 
here. Thus, in vitro studies on the myeloid THP-1 cell line has demonstrated IL-8 release requiring 5 
TL1A and IFN# priming 54, while CXCL1 is reduced in the joints of DR3-/- mice undergoing AIA 51. 6 
Both these chemokines, in humans and mice respectively, are established neutrophil attractants. This 7 
report indicates that at least in the murine SES challenge system, the production of CXCL1, but not 2 8 
other neutrophil chemoattractants (CXCL2/MIP-2 and CXCL5/LIX), is DR3-dependent. It also 9 
shows, for the first time, that there is a stromal contribution to this (Fig. 3 and 4). Whether this is the 10 
dominant DR3-dependent chemokine controlling neutrophil attraction remains an area of further 11 
study as there are multiple other chemokine/chemokine receptor interactions capable of this 
55
, many 12 
of which have not been tested in this study.  13 
 14 
The stromal release of a number of other chemokines demonstrated DR3-dependency, namely CCL2, 15 
CCL7 and CXCL13. CCL2 and CXCL13 have primary chemokine receptors, CCR2 and CXCR5 16 
respectively. CCR7 is more pleiotropic, binding CCR1, 2 and 3, together having the capacity to 17 
attract monocytes, eosinophils, DCs, T and B cells 
55
. This correlated well with the subsets of 18 
leukocytes that showed impaired SES-induced accumulation in the peritoneal cavity of DR3
-/-
 mice. 19 
Interestingly, however, there were other chemokines in DR3
-/-
 peritoneal lavage that were reduced in 20 
concentration, namely CCL3, CCL4 and CXCL10. Their ligands include CCR1, CCR5 and CXCR3 21 
found on monocytes, T, NK and mast cells. We further identified resident macrophages as a DR3-22 
dependent source of CCL3 (Fig 3C). The assumption is that CCL4 and CXCL10 were derived from 23 
other as yet unidentified leukocytes as these chemokines were either not produced or did not show 24 
DR3-dependent production by resident macrophages, while their mRNA levels were unaltered in the 25 
DR3
-/-
 mesothelium. Further studies would be required to identify which other cells are producing 26 
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DR3-dependent CCL4 and CXCL10, and determine the relative contribution of DR3 on stroma 1 
versus resident versus infiltrating leukocytes to recruitment in this system. The very rapid peak of 2 
production for many of the chemokines (less than 3 hrs – see Fig 3) would indicate either a stromal or 3 
resident leukocyte source for these, with the possibility of infiltrating leukocytes contributing to 4 
levels of chemokines at later time points.  In this context, DR3 expression on innate immune cells is 5 
constitutive on NKT cells (which have been shown to produce IL-4 and IL-13 in models of allergic 6 
lung inflammation)  
25
, or can be induced on macrophages as well as neutrophils 
51
. The latter can 7 
also produce multiple chemokines and is a major infiltrating cell type 
56
.  8 
 9 
The leukocyte recruitment function of the DR3/TL1A pathway shows distinct differences to the role 10 
that has been characterized for IL-6 using intraperitoneal SES challenge. While both impact on T cell 11 
recruitment correlating with lower levels of CCL4 and CXCL10, IL-6
-/-
 animals display a reduction 12 
in CCL5 
57
, which was not observed in DR3
-/-
 mice. Furthermore, unlike DR3
-/-
 animals, IL-6
-/-
 mice 13 
show normal early neutrophil 
46
 and later B cell 
57
 infiltration accompanied by unaltered levels of 14 
CXCL1 and CXCL13. This indicates that DR3 signaling is distinct and not directly upstream of IL-6. 15 
More recently, IL-6 has been shown to be essential for the development of peritoneal membrane 16 
fibrosis following multiple acute inflammatory episodes induced by serial applications of SES. This 17 
was attributed to IL-6-mediated Th1 effector commitment 
47
. Our data indicate that this model is also 18 
dependent on DR3, but likely through its general regulation of effector T cells. DR3
-/-
 mice are 19 
resistant to the induced increases in peritoneal membrane thickening and collagen deposition. This is 20 
consistent with the phenotype of transgenic mice overexpressing TL1A, which spontaneously 21 
develop intestinal and colonic fibrosis accompanied by goblet and Paneth cell hyperplasia  
22, 23, 58
. 22 
One significant question is the relative contribution to pathology of DR3’s role in leukocyte 23 
recruitment versus its function in driving effector cell expansion 
22, 26, 27, 29, 33, 34, 59
. While this can be 24 
divided into early and late inflammatory processes in the SES challenge model, the two 25 
immunological events are not mutually exclusive and could explain some previously observed 26 
Short title: DR3 regulates peritoneal inflammation 
 
© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
17 
phenomena, such as the altered localization of T cells and macrophages in DR3
-/-
 mice undergoing 1 
OVA-induced lung inflammation 
26
.  2 
 3 
It is evident from this work that DR3/TL1A signaling regulates primary inflammatory responses, 4 
with potential impact on downstream adjuvant and host defense activities. The understanding of these 5 
roles to pathological processes is an area of further research that will be important for developing the 6 
DR3/TL1A pathway as a therapeutic target in inflammatory disease, agonism or antagonism of which 7 
may prevent disease depending on the effector T cells being influenced. 8 
9 
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FIGURE LEGENDS 1 
Figure 1 – DR3 expression and sources of TL1A in the peritoneal cavity. Inflammation in the 2 
cavity was induced via an i.p. injection of SES. Peritoneal membranes were harvested, fixed, 3 
sectioned and stained for DR3 expression or analyzed for the relative quantity (RQ) of TL1A mRNA 4 
by qRT-PCR. A) Representative pictures showing DR3 staining in the mesothelial layer of DR3
+/+
 5 
mice after 0 and 12 hours but absent after 24 of inflammation (bar = 25µm.) B) Summary of DR3 6 
expression in the mesothelial layer. Mean % positive (brown) pixels within the mesothelial layer of 7 
the membrane shown ± SEM (n=3 to 6 DR3
+/+ 
mice and DR3
-/- 
mice per timepoint), ***p<0.001 by 8 
one-way ANOVA. C) RQ of TL1A mRNA in the peritoneal membrane of DR3
+/+ 
and DR3
-/- 
mice. 9 
Mean ± SEM from n=5 mice per timepoint; not significantly different by ANOVA. D) RQ of TL1A 10 
mRNA in DR3
+/+ 
and DR3
-/- 
resident peritoneal macrophages 1 hour after stimulation using SES. 11 
Macrophages were sorted from other leukocytes found in the peritoneal cavity from 17 pooled 12 
DR3
+/+ 
and DR3
-/- 
mice, challenged with SES and analyzed for RQ of TL1A mRNA. Mean ± SEM 13 
shown from 4 replicate experiments. *p<0.05 by t-Test assuming unequal variance. 14 
 15 
Figure 2 – Leukocyte subset numbers in the peritoneal cavity of DR3
+/+ 
and DR3
-/- 
mice after 16 
SES and MCMV induced inflammation. Inflammation in the cavity was induced via an i.p. 17 
injection of SES or MCMV. (A) Numbers of neutrophils in the peritoneal cavity following the 18 
labeled challenges at the indicated times. (B) Peritoneal leukocytes were isolated from the cavity by 19 
lavage at the indicated times post-challenge and numbers of individual cell subsets calculated using 20 
cell counts and flow cytometry. Representative data from 1 of 2 expts. Each symbol represents mean 21 
of up to 6 mice per timepoint, error bars correspond to SEM; statistical analysis by ANOVA and 22 
Bonferroni post hoc test showed significant differences between DR3
+/+
 and DR3
-/-
 mice at 23 
***p<0.001, **p<0.01, *p<0.05 for individual timepoints. Overall male:female ratio was 50:50 and 24 
matched for DR3
+/+
 and DR3
-/-
 groups. 25 
 26 
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25 
Figure 3 – Chemokine production in the peritoneal cavity of DR3
+/+ 
and DR3
-/- 
mice after SES-1 
induced inflammation. Inflammation in the cavity was induced via an i.p. injection of SES. levels of 2 
the indicated chemokines were measured in: (A) cell free supernatants in peritoneal lavage by ELISA 3 
and; (B) mRNA levels in the peritoneal membrane by qRT-PCR. Representative data from 1 of 2 4 
expts. Each symbol and error bars represent mean ± SEM from up to 6 DR3
+/+ 
and DR3
-/- 
mice per 5 
timepoint. Overall male:female ratio was 50:50 and matched for DR3
+/+
 and DR3
-/-
 groups. (C) 6 
Production of CCL3 and CCL4 by resident macrophages derived from DR3
+/+
 and DR3
-/-
 mice, 7 
stimulated with SES. Each point represents a culture; bars represent mean ± SEM. Values below the 8 
limit of the assay were assigned the lowest limit for generation of means and statistical testing. 9 
Dotted line shows lowest limit of assay. Statistical analysis by ANOVA and Bonferroni post hoc test 10 
showed significant differences between DR3
+/+
 and DR3
-/-
 mice at ***p<0.001, **p<0.01, *p<0.05. 11 
 12 
Figure 4 – Thickness of the mesothelial layer and collagen deposition in DR3
+/+ 
and DR3
-/- 
mice 13 
after inflammation induced by multiple applications of SES. Fibrosis of the mesothelial layer was 14 
induced by 4 i.p. injections of SES. Representative micrographs of the peritoneal membranes 15 
visualized with (A) hematoxylin and eosin, and (B) van Gieson stain, from mice treated as indicated. 16 
M = mesothelial layer; Bar = 50 !m. Summary of (C) mesothelial thickness and (D) collagen 17 
deposition. Bar and error bar represents mean ± SEM from up to 6 mice. Statistical analysis by 18 
ANOVA showed significant differences between DR3
+/+
 and DR3
-/-
 mice ***p<0.001 by Bonferroni 19 
post hoc test. Overall male:female ratio was 50:50 and matched for DR3
+/+
 and DR3
-/-
 groups. 20 
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Supplemental Table 1 – Counts for leukocyte subsets are not different in the unchallenged peritoneal cavity or peripheral blood of DR3-/- and 
DR3+/+ mice 
Cell subset Peritoneal cavity * Peripheral blood No/ml † 
 DR3
+/+
 DR3-/- Significance ‡ DR3+/+ DR3-/- Significance ‡ 
Macrophages/Monocytes 7.2 ± 1.8 x105 6.4 ± 1.6 x105 NS 4.2 ± 1.0 x105 4.7 ± 1.6 x105 NS 
Dendritic cells 5.1 ± 1.6 x103 3.3 ± 0.3 x103 NS N/A§ N/A§ N/A§ 
Neutrophils N/A§ N/A§ N/A§ 2.3 ± 0.6 x105 4.1 ± 2.2 x105 NS 
Eosinophils 1.9 ± 0.7 x105 7.6 ± 0.6 x104 NS 5.2 ± 1.3 x104 3.5 ± 0.8 x104 NS 
T Cells 4.5 ± 0.5 x105 4.6 ± 1.1 x105 NS 4.0 ± 0.5 x105 4.5 ± 0.6 x105 NS 
B Cells 8.6 ± 1.0 x105 9.3 ± 2.9 x105 NS 9.6 ± 1.8 x105 1.0 ± 0.2 x106 NS 
NK Cells 6.8 ± 1.7 x104 4.7 ± 0.8 x104 NS 8.3 ± 1.4 x104 7.2 ± 1.0 x104 NS 
NKT Cells 7.2 ± 1.8 x104 6.9 ± 0.6 x104 NS 1.3 ± 0.2 x104 1.3 ± 0.2 x104 NS 
 
* Values correspond to number of peritoneal leukocytes, mean ± SEM (n=5) 
† Values correspond to number of peripheral blood leukocytes/ml, mean ± SEM (n= 4 DR3+/+ or 5 DR3-/-) 
‡ Significance between the two genotypes using t-Test, NS = no significant difference  
§ N/A corresponds to subsets either not present or not tested 
 
Supplemental Table 2 – Leukocyte proliferation in the peritoneal cavity following SES challenge 
Cell Subset * Proportion of proliferating cells 
†
 
 DR3
+/+
 DR3
-/-
 Significance ‡ 
Resident macrophages 42.4 ± 13.2 44.5 ± 8.2 N.S.D 
Inflammatory macrophages 43.7 ± 11.5 47.9 ± 7.7 N.S.D 
T Cells 49.3 ± 2.3 50.5 ± 7.5 N.S.D 
B Cells 36.9 ± 2.8 28.8 ± 8.2 N.S.D 
NK Cells 35.2 ± 10.4 38.2 ± 3.8 N.S.D 
NKT Cells 47.7 ± 3.8 51.8 ± 10.1 N.S.D 
*
 
Ki67
+
 cells were assessed in the indicated cell populations using the following phenotypic criteria:  
resident macrophages (F4/80
+
CD11b
+
); inflammatory macrophages (F4/80
int
CD11b
int
); NK cells 
(NK1.1
+
!"TCR
-
); NKT cells (NK1.1
+
!"TCR
+
); T cells (CD3
+
!"TCR
+
NK1.1
-
); B cells 
(CD19
+
B220
+
) 
† 
Values = %Ki67
+
 of each subset 48 hours after SES challenge (mean ± SEM; n= 5 DR3
+/+
 or 6 
DR3
-/-
). Gating as indicated in Supplemental Figure 1. 
‡ Mann Whitney test showed N.S.D = no significant difference between DR3
+/+
 and DR3
-/-
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Figure Legends 
 
Figure 1 – Flow cytometric gating for determining Ki67+ proliferating cells. Mice 
were challenged with SES and peritoneal leukocytes isolated from the cavity by 
lavage, stained for cell subsets, permeabilised and proliferation measured using the 
intracellular marker Ki67 and DAPI to differentiate binucleate non-proliferating cells. 
Representative plots of total peritoneal leukocytes showing isotype control and KI67 
staining from DR3+/+ and DR3-/- mice. Early proliferative G1 cells (Ki67+ DAPIlo), S 
and G2M phase (Ki67
+ DAPIint/hi) and non-proliferating binucleate cells (Ki67- DAPIhi) 
shown.  
 
Figure 2 - Chemokine levels in the naïve peritoneal cavity are not different 
between DR3+/+ and DR3-/- mice. The peritoneal cavity was lavaged, cells spun 
down and chemokine concentrations in the supernatant measured by ELISA. Data 
from n=3 DR3+/+ and DR3-/- mice where available, but some values were below the 
manufacturer’s detection threshold of the ELISA and therefore excluded from 
analysis. No significant differences were detected. 
